Kisunla™
Kisunla™ (donanemab-azbt) (pronounced kih-SUHN-lah) is an amyloid-targeting treatment for people with mild cognitive impairment (MCI) as well as people with mild dementia stage of early symptomatic Alzheimer’s disease, with confirmed amyloid pathology.
Speak with your healthcare provider to learn if this drug is right for you.
WHAT IT TREATS: |
MANUFACTURER: Eli Lilly and Company |
CLASS: Monoclonal antibody |
PRESCRIBED BY: Neurologists
|
HOW ADMINISTERED: IV Infusion |
FREQUENCY: every four weeks
|
Length of infusion: 30 mins |
FOR MORE INFORMATION: |
